IL279939B2 - Thiadiazine derivatives - Google Patents

Thiadiazine derivatives

Info

Publication number
IL279939B2
IL279939B2 IL279939A IL27993921A IL279939B2 IL 279939 B2 IL279939 B2 IL 279939B2 IL 279939 A IL279939 A IL 279939A IL 27993921 A IL27993921 A IL 27993921A IL 279939 B2 IL279939 B2 IL 279939B2
Authority
IL
Israel
Prior art keywords
disorder
disorders
formula
thiadiazine
dioxo
Prior art date
Application number
IL279939A
Other languages
English (en)
Hebrew (he)
Other versions
IL279939A (en
IL279939B1 (en
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of IL279939A publication Critical patent/IL279939A/en
Publication of IL279939B1 publication Critical patent/IL279939B1/en
Publication of IL279939B2 publication Critical patent/IL279939B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL279939A 2018-07-13 2019-07-12 Thiadiazine derivatives IL279939B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1800249A HU231414B1 (hu) 2018-07-13 2018-07-13 Tiadiazin származékok
PCT/IB2019/055949 WO2020012423A1 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives

Publications (3)

Publication Number Publication Date
IL279939A IL279939A (en) 2021-03-01
IL279939B1 IL279939B1 (en) 2024-09-01
IL279939B2 true IL279939B2 (en) 2025-01-01

Family

ID=89992726

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279939A IL279939B2 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives

Country Status (23)

Country Link
US (2) US12194050B2 (https=)
EP (1) EP3820865A1 (https=)
JP (2) JP7440486B2 (https=)
KR (1) KR20210033003A (https=)
CN (1) CN112424198A (https=)
AR (1) AR115783A1 (https=)
AU (1) AU2019300515B2 (https=)
BR (1) BR112020027016A2 (https=)
CA (1) CA3104264A1 (https=)
CL (1) CL2021000081A1 (https=)
CO (1) CO2021001224A2 (https=)
CU (1) CU24622B1 (https=)
EA (1) EA202190246A1 (https=)
GE (2) GEAP202215558A (https=)
HU (1) HU231414B1 (https=)
IL (1) IL279939B2 (https=)
MX (1) MX2021000461A (https=)
MY (1) MY207757A (https=)
PE (1) PE20210465A1 (https=)
PH (1) PH12021550007A1 (https=)
SG (1) SG11202012769QA (https=)
TW (1) TWI827628B (https=)
WO (1) WO2020012423A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103191A4 (en) * 2020-02-14 2024-03-06 University of Pittsburgh - of the Commonwealth System of Higher Education HEAT SHOCK PROTEIN MODULATORS AND THERAPEUTIC AGENTS FOR HUNTINGTON'S DISEASE
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
CN111454232B (zh) * 2020-05-30 2021-11-23 南方医科大学 一种1,3,4-噻二嗪类化合物及其应用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
NZ566036A (en) 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
ES2274729B1 (es) 2005-11-11 2008-06-01 Consejo Superior Investig. Cientificas Derivados de 5-carboxilato y 5-carboxamida 2-sustituidos de 1,1-dioxo-1,2,6-tiadiazina con propiedades cannabinoides.
US20100298314A1 (en) 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
MX2010003156A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de aril amida substituida con tetrazol y usos de los mismos.
KR20100124272A (ko) 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009127678A1 (en) 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
CA2725940A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
EP2488520B1 (en) * 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
EP3795573B1 (en) 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
WO2012042915A1 (en) 2010-10-01 2012-04-05 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
SG192078A1 (en) * 2011-02-03 2013-08-30 Lupin Ltd Pyrrole derivatives used as modulators of alpha7 nachr
US9617210B2 (en) * 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
AR107928A1 (es) * 2016-03-22 2018-06-28 Merck Sharp & Dohme Moduladores alostéricos de receptores de acetilcolina nicotínicos
US10870630B2 (en) 2016-11-01 2020-12-22 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018112204A1 (en) 2016-12-14 2018-06-21 Cephalon, Inc. Spiropiperidine derivatives
SG11201908012SA (en) 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Also Published As

Publication number Publication date
CO2021001224A2 (es) 2021-02-17
HUP1800249A2 (en) 2020-01-28
US20210267993A1 (en) 2021-09-02
CA3104264A1 (en) 2020-01-16
US12194050B2 (en) 2025-01-14
IL279939A (en) 2021-03-01
IL279939B1 (en) 2024-09-01
BR112020027016A2 (pt) 2021-04-06
MX2021000461A (es) 2021-06-23
TWI827628B (zh) 2024-01-01
EA202190246A1 (ru) 2021-04-20
JP2024056879A (ja) 2024-04-23
CN112424198A (zh) 2021-02-26
WO2020012423A1 (en) 2020-01-16
CL2021000081A1 (es) 2021-10-29
EP3820865A1 (en) 2021-05-19
GEAP202215558A (en) 2022-07-25
PH12021550007A1 (en) 2021-09-20
CU20200109A7 (es) 2021-08-06
HU231414B1 (hu) 2023-08-28
JP2021529813A (ja) 2021-11-04
AU2019300515B2 (en) 2025-01-23
SG11202012769QA (en) 2021-02-25
TW202019431A (zh) 2020-06-01
AU2019300515A1 (en) 2021-02-11
MY207757A (en) 2025-03-17
CU24622B1 (es) 2022-09-08
US20250064823A1 (en) 2025-02-27
KR20210033003A (ko) 2021-03-25
PE20210465A1 (es) 2021-03-08
AR115783A1 (es) 2021-02-24
GEP20237459B (en) 2023-01-25
JP7440486B2 (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
US20250064823A1 (en) Thiadiazine derivatives
CA2705411A1 (en) Heteroaryl derivatives as orexin receptor antagonists
EP2114940A1 (en) Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
JP2013199489A (ja) 新規ピペラジン、医薬組成物、およびその使用方法
JP7487167B2 (ja) スピロクロマン誘導体
CN103443075A (zh) 作为烟碱型乙酰胆碱受体调节剂的吡咯衍生物在治疗神经变性障碍,例如阿耳茨海默氏病和帕金森氏病中的用途
CA2557054C (en) (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor
WO2020012424A1 (en) Substituted (aza)indole derivatives
OA20785A (en) Thiadiazine derivatives
HK40044485A (en) Spirochromane derivatives
HK40044485B (en) Spirochromane derivatives
OA20784A (en) Spirochromane derivatives
EA043926B1 (ru) Производные спирохромана
EA035585B1 (ru) Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов